Tyler Bland, Ph.D.
Tyler Bland, Ph.D.
Clinical Assistant Professor
- 2013, BS in Biochemistry, Whitworth University
- 2017, PhD in Neuroscience, Washington State University
- 2020, Postdoctoral Fellowship in Prostate Cancer Biology, Washington State University
Current work in Dr. Bland’s laboratory is aimed at understanding the mechanism of cancer drug resistance, with special focus on chemotherapy resistance in non-small cell lung cancer (NSCLC) and the potential for repurposing drugs from other areas of the clinic as treatments for this lethal disease.
Dr. Bland has a diverse background in biochemistry, neuroscience, cancer biology, and pharmacology. He is the pharmacology site lead in the WWAMI Program at the University of Idaho.Selected Publications:
- Bland T, Wang, J, Yin, L, Pu, T, Li, J, Gao, J, Lin, T-P, Gao, A. C., and Wu, B. J. (2021) WLS-Wnt signaling promotes neuroendocrine prostate cancer. iScience. 24, 101970
- Bland T, Zhu M, Dillon C, Sahin GS, Rodriguez-Llamas JL, Appleyard SM, Wayman GA (2020) Leptin controls glutamatergic synaptogenesis and NMDA-receptor trafficking via Fyn kinase regulation of NR2B. Endocrinology 161(2):1-14
- Bland T, Glucan S, Zhu M, Dillon C, Impey S, Appleyard SM, Wayman GA (2019) USP8 deubiquitinates the leptin receptor and is necessary for leptin-mediated synapse formation. Endocrinology. 160:1982-1998"